Oviva Therapeutics is a women’s health technology service provider, focusing on the prevention of ovarian aging, dedicated to research and clinical development of treatments that address women’s physiology, starting with attention to ovarian aging and addressing the huge unmet needs in women’s health. announced today that it has secured $11.5 million in seed funding from longevity biotech company Cambrian Biopharma.
This article is reproduced from: https://www.itjuzi.com/investevent/13251989
This site is for inclusion only, and the copyright belongs to the original author.